Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BN301 in Advanced B-cell Non-Hodgkin's Lymphoma
NCT05611853Phase 2Terminated
- Sponsor
- BioNova Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of STRO-001 in B-cell non-Hodgkin lymphoma (3 arms), sponsored by BioNova Pharmaceuticals. Primary endpoints: Incidence of Treatment-Related Adverse Events at 12 months and Objective Response Rate at 2 years. Started Nov 2022; status: terminated.
02
Drugs
STRO-001
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05611853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05611853.